Literature DB >> 8770427

Paracetamol self-poisoning. Characteristics, prevention and harm reduction.

K Hawton1, C Ware, H Mistry, J Hewitt, S Kingsbury, D Roberts, H Weitzel.   

Abstract

BACKGROUND: Paracetamol is now the most common drug used for self-poisoning in the UK and is associated with potentially fatal liver damage. Patients admitted to hospital because of paracetamol overdoses were studied in order to determine their characteristics and factors which might have deterred them from taking paracetamol or reduced the dangers of the overdose.
METHOD: Eighty patients were studied in hospital using a structured interview schedule, measures of depression and suicidal intent, information collected through the Oxford Monitoring System for Attempted Suicide, and the results of liver function tests.
RESULTS: Acute liver dysfunction (25 patients) was associated with consumption of more than 25 tablets (odds ration 4.46, 95% CI 1.31 to 17.41, P = 0.014). The proportionate use of tablets from blister packs (60%) and loose preparations (46%; 5 patients using both types) reflected their general availability. More of those who took tablets from a loose preparation consumed 25 or more tablets (69%) than those who used a blister-pack preparation (40%; odds ratio = 3.0, 95% CI 1.12 to 9.95, P = 0.028). Only 20 patients thought that any type of warning label would have deterred them from taking a paracetamol overdose.
CONCLUSIONS: Establishing a maximum number of tablets (e.g. 25) that can be available in individual preparations is likely to reduce the dangers of paracetamol self-poisoning. The potential effects of other measures are uncertain.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8770427     DOI: 10.1192/bjp.168.1.43

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  34 in total

Review 1.  Management of self poisoning.

Authors:  A L Jones; G Volans
Journal:  BMJ       Date:  1999-11-27

2.  "Late presenters" after paracetamol self poisoning.

Authors:  M P Bradley; J S Nguyen-Van-Tam; J C Pearson
Journal:  J Epidemiol Community Health       Date:  1998-11       Impact factor: 3.710

3.  Effects of legislation restricting pack sizes of paracetamol and salicylate on self poisoning in the United Kingdom: before and after study.

Authors:  K Hawton; E Townsend; J Deeks; L Appleby; D Gunnell; O Bennewith; J Cooper
Journal:  BMJ       Date:  2001-05-19

Review 4.  Acetaminophen (APAP) hepatotoxicity-Isn't it time for APAP to go away?

Authors:  William M Lee
Journal:  J Hepatol       Date:  2017-07-20       Impact factor: 25.083

5.  Paracetamol availability and recent changes in paracetamol poisoning: is the 1998 legislation limiting availability of paracetamol being followed?

Authors:  S L Greene; P I Dargan; P Leman; A L Jones
Journal:  Postgrad Med J       Date:  2006-08       Impact factor: 2.401

6.  Use of paracetamol for suicide and non-fatal poisoning in the UK and France: are restrictions on availability justified?

Authors:  D Gunnell; K Hawton; V Murray; R Garnier; C Bismuth; J Fagg; S Simkin
Journal:  J Epidemiol Community Health       Date:  1997-04       Impact factor: 3.710

7.  Psychosocial and behavioral factors in acetaminophen-related acute liver failure and liver injury.

Authors:  Carla Pezzia; Corron Sanders; Suzanne Welch; Angela Bowling; William M Lee
Journal:  J Psychosom Res       Date:  2017-08-04       Impact factor: 3.006

8.  Pack-size legislation reduces severity of paracetamol overdoses in Ireland.

Authors:  E Donohoe; N Walsh; J A Tracey
Journal:  Ir J Med Sci       Date:  2006 Jul-Sep       Impact factor: 1.568

9.  The use of over-the-counter drugs among surgical and medical patients.

Authors:  Bente Glintborg; Stig Ejdrup Andersen; Eva Spang-Hanssen; Kim Dalhoff
Journal:  Eur J Clin Pharmacol       Date:  2004-06-10       Impact factor: 2.953

10.  Detailed analyses of self-poisoning episodes presenting to a large regional teaching hospital in the UK.

Authors:  Katherine Prescott; Richard Stratton; Anette Freyer; Ian Hall; Ivan Le Jeune
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.